Equifax Q1 revenue $1.389B (+7% YoY); maintains FY2024 guidance

EQUIFAX INC

2024-Q1 EPS reported $1.00 revenue$1,389,400,000

Revenue $1.389B (+7% reported, +8% local currency); diluted EPS $1.00; adj. EPS $1.50 (+5% YoY).
Workforce Solutions revenue $602.8M (+1%); USIS revenue $465.3M (+10%, strongest in 3 years).
International revenue $321.3M (+13% reported, +20% local currency); Latin America +65% (reported).
Full-year 2024 guidance maintained: revenue midpoint $5.720B (+8.6% reported), adj. EPS $7.35.
US mortgage revenue +6% despite -19% USIS mortgage inquiries; non-mortgage ~80% of rev grew 9% LCY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

EQUIFAX INC reported the quarter ended March 31, 2024 results: revenue $1,389.4 million, net income $124.9 million, EPS $1.00 per share. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $1,389.4 million
Net income: $124.9 million
EPS: $1.00 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

The Company reported revenue of $1,389.4 million in the first quarter of 2024, up 7 percent on a reported basis and up 8 percent on a local currency basis compared to the first quarter of 2023. Net income attributable to Equifax of $124.9 million was up 11 percent in the first quarter of 2024 compared to $112.4 million in the first quarter of 2023. Diluted EPS attributable to Equifax was $1.00 per share for the first quarter of 2024, up 10 percent compared to $0.91 per share in the first quarter of 2023.

View on SEC.gov

521 earnings releases filed in the last 30 days. Browse all earnings releases →

EQUIFAX INC filing history →

Source: SEC EDGAR

accession 0000033185-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.